Report of Foreign Issuer (6-k)
30 June 2016 - 2:19AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
F O R M 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June, 2016
TRINITY
BIOTECH PLC
(Name of Registrant)
IDA Business
Park
Bray, Co. Wicklow
Ireland
(Address of
Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or
Form 40-F.
Form
20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
¨
No
x
If Yes is marked,
indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
Press Release dated June 29, 2016
|
|
|
|
|
|
|
|
|
|
|
Contact:
|
|
Trinity Biotech plc
Kevin
Tansley
(353)-1-2769800
E-mail:
kevin.tansley@trinitybiotech.com
|
|
|
|
Lytham Partners LLC
Joe Diaz, Joe
Dorame & Robert Blum
602-889-9700
|
DUBLIN, Ireland (June 29, 2016)
Trinity Biotech plc
(Nasdaq: TRIB), today entered into a 10b5-1 plan to continue the repurchase of shares during the close period, in connection with its share buyback programme previously announced on March 3, 2016.
Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to,
the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties,
and other risks detailed in the Companys periodic reports filed with the Securities and Exchange Commission.
Trinity Biotech develops,
acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify
the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners
in over 75 countries worldwide. For further information please see the Companys website:
www.trinitybiotech.com
.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
TRINITY BIOTECH PLC
|
(Registrant)
|
|
|
By:
|
|
/s/ Kevin Tansley
|
|
|
Kevin Tansley
Chief Financial
Officer
|
Date: June 29, 2016.
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Apr 2024 to May 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From May 2023 to May 2024